22.04
Schlusskurs vom Vortag:
$22.82
Offen:
$23.04
24-Stunden-Volumen:
83,711
Relative Volume:
0.22
Marktkapitalisierung:
$304.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.48M
KGV:
-15.05
EPS:
-1.4641
Netto-Cashflow:
$-8.59M
1W Leistung:
+2.98%
1M Leistung:
-4.16%
6M Leistung:
+96.19%
1J Leistung:
+150.62%
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Firmenname
Greenwich Lifesciences Inc
Sektor
Branche
Telefon
203-434-3290
Adresse
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
GLSI
Greenwich Lifesciences Inc
|
22.00 | 316.16M | 0 | -19.48M | -8.59M | -1.4641 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.53 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.09 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.56 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
INSM
Insmed Inc
|
163.57 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-20 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-09-01 | Eingeleitet | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Aktie (GLSI) Neueste Nachrichten
Greenwich LifeSciences Delays Annual SEC Filing - tipranks.com
Greenwich LifeSciences (GLSI) notifies SEC of late 10-K, cites higher R&D - Stock Titan
Sell Signal: What are the future prospects of Greenwich LifeSciences Inc2026 Market Overview & Long-Term Investment Growth Plans - baoquankhu1.vn
(GLSI) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Greenwich LifeSciences (GLSI) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Aug Analyst Calls: What are the future prospects of Greenwich LifeSciences IncPortfolio Value Summary & Real-Time Market Trend Scan - baoquankhu1.vn
GLSI Technical Analysis | Trend, Signals & Chart Patterns | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
If You Invested $1,000 in Greenwich Lifesciences Inc (GLSI) - Stock Titan
Retail Trends: Is Greenwich LifeSciences Inc undervalued by DCF analysisGold Moves & Weekly Top Performers Watchlists - baoquankhu1.vn
Treasury Yields: Is Greenwich LifeSciences Inc a turnaround storyWeekly Profit Analysis & Long Hold Capital Preservation Plans - baoquankhu1.vn
Greenwich LifeSciences expands Phase III trial to City of Hope sites - ca.investing.com
Greenwich LifeSciences Inc initiates new US clinical sites for Flamingo-01 phase III trial - marketscreener.com
Greenwich LifeSciences, Inc. Announces Addition of City of Hope to Flamingo-01 - marketscreener.com
Greenwich LifeSciences Expands FLAMINGO-01 Trial to City of Hope - National Today
Greenwich LifeSciences expands Phase III trial to City of Hope sites By Investing.com - Investing.com India
Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01 - ChartMill
Liquidity Mapping Around (GLSI) Price Events - news.stocktradersdaily.com
Greenwich LifeSciences to present trial data at AACR meeting By Investing.com - Investing.com South Africa
Greenwich LifeSciences to present trial data at AACR meeting - Investing.com
Greenwich Lifesciences provides update on upcoming AACR meeting - marketscreener.com
Greenwich Lifesciences Provides Update On Upcoming Aacr Meeting - TradingView
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting - manilatimes.net
Greenwich LifeSciences, Inc. Announces Presentation of FLAMINGO-01 Phase III Clinical Trial Data at AACR Meeting 2026 - Quiver Quantitative
Greenwich LifeSciences to share AACR Meeting plans - Traders Union
Greenwich LifeSciences reports reduced cancer recurrence in trial By Investing.com - Investing.com South Africa
Why is GLSI stock rising today? - MSN
Breakthrough in Clinical Trial Data: Biopharmaceutical company Greenwich Lifesciences Inc (NASDAQ: GLSI) recently announced the latest analysis results of its core immunotherapy GP2 in adjuvant treatment for breast cancer. - Bitget
Why Is GLSI Stock Rising Today? - Mena FN
Greenwich LifeSciences reports reduced cancer recurrence in trial - Investing.com
Greenwich LifeSciences provides update showing continued reduction in recurrence rate in the open label arm of Flamingo-01 - marketscreener.com
Greenwich Lifesciences Provides Update Showing Continued Reduction In Recurrence Rate In The Open Label Arm Of Flamingo-01 - TradingView
Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01 - manilatimes.net
Greenwich LifeSciences Provides Update Showing Continued - GlobeNewswire
Greenwich LifeSciences begins using commercial GP2 at US sites By Investing.com - Investing.com Australia
Greenwich LifeSciences begins using commercial GP2 at US sites - Investing.com
Greenwich LifeSciences Provides Update on Phase III Clinical Trial FLAMINGO-01 and Commercial Manufacturing of GP2 - Quiver Quantitative
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01 - GlobeNewswire
Big Money Moves: Is Greenwich LifeSciences Inc undervalued by DCF analysisPortfolio Performance Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6% – Should You Buy? - Defense World
Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6%Should You Buy? - MarketBeat
Why (GLSI) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Why did Greenwich LifeSciences stock soar pre-market today? - MSN
ETF Watch: Is Greenwich LifeSciences Inc a turnaround storyWeekly Investment Recap & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Market Review: Is Greenwich LifeSciences Inc a stock for growth or value investorsMarket Activity Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
GLSI Should I Buy - Intellectia AI
Finanzdaten der Greenwich Lifesciences Inc-Aktie (GLSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Greenwich Lifesciences Inc-Aktie (GLSI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Jan 12 '26 |
Buy |
27.54 |
2,900 |
79,866 |
5,602,302 |
| Patel Snehal | CEO and CFO |
Dec 31 '25 |
Buy |
21.36 |
4,300 |
91,848 |
5,599,402 |
| Patel Snehal | CEO and CFO |
Dec 30 '25 |
Buy |
21.73 |
2,900 |
63,017 |
5,595,102 |
| Patel Snehal | CEO and CFO |
Dec 18 '25 |
Buy |
12.62 |
4,100 |
51,742 |
5,592,202 |
| Patel Snehal | CEO and CFO |
Nov 25 '25 |
Buy |
8.37 |
4,600 |
38,502 |
5,588,102 |
| Patel Snehal | CEO and CFO |
Nov 07 '25 |
Buy |
8.43 |
10,600 |
89,358 |
5,583,502 |
| Patel Snehal | CEO and CFO |
Oct 31 '25 |
Buy |
9.26 |
2,300 |
21,298 |
5,572,902 |
| Patel Snehal | CEO and CFO |
Apr 25 '25 |
Buy |
9.88 |
3,600 |
35,568 |
5,570,602 |
| Patel Snehal | CEO and CFO |
Apr 17 '25 |
Buy |
8.98 |
5,400 |
48,492 |
5,567,002 |
| Patel Snehal | CEO and CFO |
Apr 07 '25 |
Buy |
9.10 |
3,600 |
32,760 |
5,561,602 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):